
New Drug Prevents Pancreatic Cancer in 90% of Trial Patients
An experimental drug safely activated immune responses against pancreatic cancer in 90% of high-risk patients, offering hope for preventing one of the deadliest cancers. After two years, none of the participants developed cancer.


















